AYTU BIOPHARMA, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$15M
↓-6.5% -$1Mvs FY2024 (Q4)
Gross Profit
$10M
↓-10.8% -$1Mvs FY2024 (Q4)
Operating Income
$9M
↓-6.9% -$690Kvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $15M | $16M |
| COGS | $6M | $5M |
| Gross Profit | $10M | $11M |
| R&D | $0 | $522K |
| SG&A | $0 | $0 |
| D&A | $100K | $100K |
| Other OpEx | $190K | $140K |
| Operating Income | $9M | $10M |
| Interest Exp. | $560K | $1M |
| Other Non-Op | $9M | $9M |
| Pretax Income | $0 | $382K |
| Tax | $0 | $283K |
| Net Income | $0 | $99K |
QuarterCharts · SEC EDGAR data · AYTU · Comparing FY2025 (Q4) vs FY2024 (Q4)